ГоловнаArchive of numbers2019Volume 27, issue 4 (101)Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats
Title of the article Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats
Authors Stoianov Oleksandr
In the section MECHANISMS OF FORMATION AND MODERN PRINCIPLES OF TREATMENT OF NEUROLOGICAL DISORDERS
Year 2019 Issue Volume 27, issue 4 (101) Pages 25-31
Type of article Scientific article Index UDK 615. 015: 616-001.8 Index BBK -
Abstract Brain vascular pathology is one of the leading causes of mortality, the main cause of disability and life quality decrease throughout the world. Ukraine demonstrate a steady tendency to increase the prevalence and incidence of cerebrovascular pathology over the past 10—15 years, especially chronic progressive forms. Oxidative stress is one of the leading ischemic brain damage cause. To suppress it the main modern approaches in cerebrovascular pathology pharmacological treatment search are connected. The use of the antioxidant 2-ethyl- 6-methyl-3-hydroxypyridine succinate as a pathogenetically necessary agent in conditions of ischemic brain damage during bilateral occlusion of the common carotid arteries in rats in order to study the eff ectiveness of therapy is experimentally substantiated in the article. 4 groups of animals were used in experimental conditions. Rats motor activity in the "open fi eld" test, trembling and stiff ness, a "humpiness" symptom, muscular activity and neurological status were determined on the 2nd, 5th, 7th, 14th and 28th days of the experimental trials. Rats after reproducing ischemia of the brain showed hypokinesia, discoordination, muscle rigidity, severe neurological defi ciency. Mexicor administered in doses of 50 mg/kg and 100 mg/kg contributed to a dose-dependent decreasing of the studied indexes. The eff ectiveness of using mexicor signifi cantly exceeded the results obtained in the group without treatment. A dose-dependent eff ect was recorded with a signifi cant diff erence with increasing dosage. Thus, behavioral, muscular, coordinative and neurological correlates of chronic cerebral ischemia induced by carotid arteries occlusion gone during 14—28 days in conditions of mexicor effi cacy. The experimental results obtained are the background for a clinical examinations further series of patients with chronic cerebral ischemia using Mexicor as one of the components of ischemic brain damage complex pathogenetically based pharmacocorrection.
Key words experimental ischemia, 2-ethyl-6-methyl-3-hydroxypyridine succinate, pathogenetic treatment, ischemic brain damage pharmacocorrection
Access to full text version of the article pdf download
Bibliography


1. Mischenko T. S., Zdesenko I. V., Mischenko V. N. Novyie vozmozhnosti v lechenii bolnyih s distsirkulyatornoy entsefalopatiey // Mezhdunarodnyiy nevrologicheskiy zhurnal. 2015.№ 5 (75). S. 55—64.
2. Mischenko T. S., Mischenko V. N., Lapshina I. A. Bilobilintens v lechenii bolnyih s distsirkulyatornoy entsefalopatiey,obuslovlennoy aterosklerozom i arterialnoy gipertenziey //Tam zhe. 2015. № 4 (74). S. 29—34.
3. Antipenko E. A., Gustov A. V. Hronicheskaya ishemiya golovnogo mozga sovremennoe sostoyanie problemyi // Meditsinskiy sovet. 2016. № 19. S. 38—43. DOI: https://doi.org/10.21518/2079-701X-2016-19-38-43.
4. Epidemiologiya i faktoryi riska razvitiya ishemicheskogo insulta / Karpova E. N., Muravev K. A., Muraveva V. N. [i dr.] // Sovremennyie problemyi nauki i obrazovaniya. 2015. №4. URL :http://www.science-education.ru/ru/article/view?id=20768.
5. Povrezhdeniya travmaticheskogo i gipoksicheskogo geneza: obschnost patogeneticheskih mehanizmov / R. S. Vastyanov, A. N. Stoyanov, V. M. Demidov [i dr.] = Traumatic and hypoxic damages: common pathogenetic mechanisms / R. S. Vastyanov, A. N. Stoyanov, V. M. Demidov [et al.] // Journal of Education, Health and Sport. 2016: 6 (9): 285—304. DOI: http://dx.doi.org/10.5281/zenodo.61768.
6. Volohova G. O., Stoyanov O. M. DoslIdzhennya perebIguperoksidnih mehanIzmIv v parenhImI mozku v patogenezI IshemIchnogo Insultu // Vestnik neotlozhnoy i vosstanovitelnoy meditsinyi. 2009. T. 10, № 2. S. 210—212.
7. Intensifikatsiya protsessov lipoperoksidatsii i ugnetenie aktivnosti antiradikalnyih mehanizmov kak odnonapravlennyie mehanizmyi povrezhdeniya mozga pri ChMT i insulte /G. A. Volohova, A. N. Stoyanov, R. S. Vastyanov, S. I. Dribina //UkraYinskiy nevrologIchniy zhurnal. 2010. № 1. S. 112—119.
8. Mischenko T. S., Mischenko V. N., Lapshina I. A. Ispolzovanie preparata meksiprim v lechenii bolnyih s distsirkulyatornoy entsefalopatiey: dannyie issledovaniya Kaskad // LIki UkraYini. 2012. № 3—4 (2). S. 11—14.
9. Solovev N. A., Vik V. Ya. Eksperimentalno-klinicheskoe issledovanie deystviya Meksidola pri nekotoroy patologii. Vyiyasnenie vozmozhnoy lokalizatsii i mehanizma deystviya // Byulleten eksperimentalnoy biologii i meditsinyi. 2006, prilozhenie 1. S. 230—241.
10. Voronina T. A. Otechestvennyiy preparat novogo pokoleniya meksidol: osnovnyie effektyi, mehanizm deystviya,primenenie. M., 2004. 22 s.
11. Voronina T. A., Nerobkova L. N. Rukovodstvo po eksperimentalnomu (doklinicheskomu) izucheniyu novyih farmakologicheskih veschestv / pod red. V. P. Fisenko. M., 2000. S. 138—146.
12. Dyumaev K. M., Voronina T. A., Smirnov L. D. Antioksidantyi v profilaktike i terapii patologiy TsNS. M., 1995. 271 s.
13. Lechebnaya effektivnost meksidola pri tyazheloy mehaniches koy travme, sochetannoy s gipotireozom, v eksperimente / Zolotuhin S. E., Mahneva A. V., Shpachenko N. N. [i dr.] // Travma.T. 12, № 4, 2011. S. 86—89.
14.Voronina T. A. Antioksidant meksidol. Osnovnyie neyropsihotropnyie effektyi i mehanizm deystviya // Psihofarmakologiya i biologicheskaya narkologiya. 2001. T. 1, № 1. S. 2-12.
15. Voronina T. A. Meksidol. Osnovnyie effektyi, mehanizm deystviya, primenenie. M., 2003. 231 s. 16. Modelirovanie funktsionalnoy nedostatochnosti nigrostriarnoy dofaminergicheskoy sistemyi u myishey / Haindrava V. G., Kozina E. A., Kudrin B. C. [i dr.] // Zhurnal nevrologii i psihiatrii im. I. M. Sechenova. 2010. S. 87—92.
17. Ugryumov M. V. Traditsionnyie i novyie predstavleniya o patogeneze, diagnostike i lechenii neyrodegenerativnyih zabolevaniy // Neyrodegenerativnyie zabolevaniya: fundamentalnyie i prikladnyie aspektyi / pod red. M. V. Ugryumova. M. : Nauka, 2010. S. 8—35.
18. Katunina E. A. Antioksidantnaya terapiya v kompleksnom lechenii bolezni Parkinsona // RMZh. 2010. № 8. S. 468.
19. Byresh Ya., Byreshova O., Hyucton D. Metodiki i osnovnyieeksperimentyi po izucheniyu mozga i povedeniya. M. : Vyisshaya shkola, 1991. 400 s.
20. Sliesarchuk V. Yu., Mamchur V. Y. Neiroprotektorni efekty preparativ kvertsetynu pry hostromu porushenni mozkovoho krovoobihu v eksperymenti // Odeskyi medychnyi zhurnal.2008. № 4 (108). S. 3—6.
21. Gannushkina I. V. Funktsionalnaya angioarhitektonika golovnogo mozga. M. : Meditsina, 1977. 119 s.
22. Naloxone effect on the neurological deficit induced by forebrain ischemia in rats / Capdeville C., Pruneau D., Allix M. [et al.] // Life Sci. 1986. Vol. 38, No. 5. P. 437—442. DOI: 10.1016/0024-3205(86)90068-8.
23. Nagafuji T., Koide T., Takato M. Neurochemical correlates of selective neuronal loss following cerebral ischemia — role of decreased Na+, K+-ATPase activity // Brain Research. 1992. Vol. 571, No. 2. P. 265—271. DOI: https://doi.org/10.1016/0006-8993(92)90664-U.
24. Effects of delta-sleep-inducing peptide in cerebral ischemia in rats / Shandra A. A., Godlevskii L. S., Brusentsov A. I. [et al.] // Neurosci. Behav. Physiol. 1998. Vol. 28, No. 4. P. 443—446. DOI: 10.1007/bf02464804.
25. Myslobodsky M., Kofman O., Mintz M. Convulsant specific architecture of postictal behavioral syndrome in the rat // Epi lepsia. 1981. Vol. 27, No. 4. P. 559—568. DOI: 10.1111/j.1528-1157.1981.tb04127.x.
26. Gannushkina I. V. Funktsionalnaya angioarhitektonika golovnogo mozga. M. : Meditsina, 1977. 119 s.